Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®

$17 million in cash and cash equivalents as of June 30, 2026

Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide

CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

"The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR's differentiated clinical profile," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology.

"Following the quarter end, we completed the nationwide deployment of Citius Oncology's expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR's success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures," added Mazur.

"We also continued to advance LYMPHIR's longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT ® & CIBMTR ® Tandem Meetings, showed an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR's potential beyond cutaneous T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR," concluded Mazur.

Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments

Fiscal Third Quarter 2026 Financial Highlights and Subsequent Developments

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok ®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to regain compliance with Nasdaq's continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain regulatory approval for and commercialize or enter into strategic partnerships with respect to Mino-Lok and Halo-Lido; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and as amended on January 28, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:

Ilanit Allen

[email protected]

908-967-6677 x113

Media Contact:

STiR-communications

Greg Salsburg

[email protected]

– Financial Tables Follow –

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

June 30,

September 30,

2026

2025

ASSETS

Current Assets:

Cash and cash equivalents

17,007,523

4,252,290

Accounts receivable, net of allowances

686,235

Inventory

22,625,945

22,286,693

Prepaid expenses

3,011,660

1,395,490

Total Current Assets

43,331,363

27,934,473

Operating lease right-of-use asset, net

753,039

818,694

Deposits

38,062

In-process research and development, net of accumulated amortization

88,785,938

92,800,000

Goodwill

9,346,796

Total Other Assets

98,170,796

102,184,858

Total Assets

142,255,198

130,938,025

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable

8,037,899

13,693,692

License payable

15,650,000

22,650,000

Accrued expenses

25,913,962

4,190,253

Accrued compensation

1,871,320

3,292,447

Note payable

1,000,000

Operating lease liability

176,170

88,348

Total Current Liabilities

51,649,351

44,914,740

Deferred tax liability

7,696,443

7,770,760

Notes payable, net of deferred financing fees

6,410,161

Operating lease liability – noncurrent

590,787

724,925

Total Liabilities

66,346,742

53,410,425

Commitments and Contingencies

Stockholders' Equity:

Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued

and outstanding

Common stock - $0.001 par value; 250,000,000 shares authorized; 27,452,570 and

18,067,744 shares issued and outstanding at June 30, 2026 and September 30, 2025,

respectively

27,452

18,068

Additional paid-in capital

343,704,577

306,336,239

Accumulated deficit

(277,118,897)

(238,804,129)

Total Citius Pharmaceuticals, Inc. Stockholders' Equity

66,613,132

67,550,178

Non-controlling interest

9,295,324

9,977,422

Total Equity

75,908,456

77,527,600

Total Liabilities and Equity

142,255,198

130,938,025

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025

(Unaudited)

Three Months Ended

Nine Months Ended

June 30,

2026

2025

2026

2025

Revenues

1,493,788

—

7,105,197

—

Cost of revenues

(491,843)

—

(1,609,929)

—

Gross Profit

1,001,945

—

5,495,268

—

Operating Expenses

Research and development

1,053,869

1,621,325

4,287,106

7,514,888

Amortization of in-process research and development

1,720,312

—

4,014,062

—

General and administrative

6,149,173

4,447,008

38,261,001

14,626,882

Stock-based compensation – general and administrative

3,810,665

2,719,674

11,879,167

7,946,529

Total Operating Expenses

12,734,019

8,788,007

58,441,336

30,088,299

Operating Loss

(11,732,074)

(8,788,007)

(52,946,068)

(30,088,299)

Other Income (Expense)

Interest income

116,691

20,637

215,372

56,658

Gain on sale of New Jersey net operating losses

—

3,833,277

—

Amortization of deferred financing costs

(179,492)

—

(179,492)

—

Interest expense

(231,732)

(172,262)

(420,301)

(172,262)

Total Other Income (Expense), Net

(294,533)

(151,625)

3,448,856

(115,604)

Loss before Income Taxes

(12,026,607)

(8,939,632)

(49,497,212)

(30,203,903)

Income tax expense (benefit)

(107,347)

264,240

(74,317)

792,720

Net Loss

(11,919,260)

(9,203,872)

(49,422,895)

(30,996,623)

Net loss attributable to non-controlling interest

3,056,417

414,000

11,108,127

1,522,000

Net loss applicable to common stockholders

(8,862,843)

(8,789,872)

(38,314,768)

(29,474,623)

Net Loss Per Share - Basic and Diluted

(0.34)

(0.80)

(1.64)

(3.27)

Weighted Average Common Shares Outstanding

Basic and diluted (includes pre-funded warrants)

26,169,589

11,006,896

23,343,869

9,020,356

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED JUNE 30, 2026 AND 2025

(Unaudited)

2026

2025

Cash Flows From Operating Activities:

Net loss

(49,422,895)

(30,996,623)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense

11,879,167

7,946,529

Issuance of common stock for services

107,510

—

Issuance of common stock warrant

68,597

—

Amortization of in-process research and development

4,014,062

—

Amortization of operating lease right-of-use asset

65,655

152,212

Amortization of deferred financing costs

179,492

—

Deferred income tax expense (benefit)

(74,317)

792,720

Changes in operating assets and liabilities:

Accounts receivable, net of allowances

(686,235)

—

Inventory

(339,252)

(8,940,201)

Prepaid expenses

(1,616,170)

1,386,824

Accounts payable

(5,655,793)

5,166,831

Accrued expenses

19,961,209

8,506,648

Accrued compensation

(1,421,127)

1,481,023

Operating lease liability

(46,316)

(167,911)

Net Cash Used In Operating Activities

(22,986,413)

(14,671,948)

Cash Flows From Investing Activities:

License fee payments

(7,000,000)

—

Net Cash Used in Investing Activities

(7,000,000)

—

Cash Flows From Financing Activities:

Proceeds from (repayment of) note payable and advance from employee

(1,000,000)

1,300,000

Repayment of advance from employee

(300,000)

Net proceeds from loan agreement

9,635,000

—

Proceeds from exercise of warrants

9,731,103

—

Deferred Financing Costs

(892,551)

—

Proceeds from sale of Series A preferred stock

—

100

Redemption of Series A preferred stock

—

(100)

Net proceeds from common stock offerings

25,268,094

16,509,194

Net Cash Provided By Financing Activities

42,741,646

17,509,194

Net Change in Cash and Cash Equivalents

12,755,233

2,837,246

Cash and Cash Equivalents - Beginning of Period

4,252,290

3,251,880

Cash and Cash Equivalents - End of Period

17,007,523

6,089,126

Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:

Interest paid

303,644

—

Operating lease right-of-use asset and liability recorded

—

786,697

Warrants issued for loan agreement included in deferred financing costs

749,280

—

Deferred financing costs included in accrued expenses

1,762,500

—

SOURCE Citius Pharmaceuticals, Inc.